NVCT vs. ATXS, ORGO, KMDA, KALV, ABVX, AURA, RVNC, ALLO, PRME, and KOD
Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Astria Therapeutics (ATXS), Organogenesis (ORGO), Kamada (KMDA), KalVista Pharmaceuticals (KALV), ABIVAX Société Anonyme (ABVX), Aura Biosciences (AURA), Revance Therapeutics (RVNC), Allogene Therapeutics (ALLO), Prime Medicine (PRME), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.
Nuvectis Pharma vs.
Nuvectis Pharma (NASDAQ:NVCT) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking.
Astria Therapeutics' return on equity of -43.58% beat Nuvectis Pharma's return on equity.
Nuvectis Pharma currently has a consensus target price of $21.00, suggesting a potential upside of 228.64%. Astria Therapeutics has a consensus target price of $25.60, suggesting a potential upside of 237.51%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Astria Therapeutics is more favorable than Nuvectis Pharma.
Nuvectis Pharma is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Astria Therapeutics received 558 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.00% of users gave Nuvectis Pharma an outperform vote while only 72.97% of users gave Astria Therapeutics an outperform vote.
96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 35.8% of Nuvectis Pharma shares are held by company insiders. Comparatively, 2.9% of Astria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Nuvectis Pharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
In the previous week, Astria Therapeutics had 4 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Astria Therapeutics and 1 mentions for Nuvectis Pharma. Astria Therapeutics' average media sentiment score of 0.12 beat Nuvectis Pharma's score of 0.00 indicating that Astria Therapeutics is being referred to more favorably in the news media.
Summary
Astria Therapeutics beats Nuvectis Pharma on 12 of the 16 factors compared between the two stocks.
Get Nuvectis Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvectis Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:NVCT) was last updated on 1/27/2025 by MarketBeat.com Staff
Free NVCT Stock Alerts